JMKX001899 + midazolam + dextromethorphan + rosuvastatin + digoxin

This is a **combination of five drugs**: - **JMKX001899** is a potent, selective, irreversible small molecule inhibitor of KRAS G12C, in clinical development for KRAS G12C-mutated non-small cell lung cancer, including patients with brain metastases. It locks KRAS G12C in its inactive state, inhibiting tumor growth[3][1][7]. - **Midazolam** is a short-acting benzodiazepine used for sedation, anesthesia, and control of seizures, acting primarily as a positive allosteric modulator at the GABA-A receptor. - **Dextromethorphan** is a morphinan-class antitussive (cough suppressant) that acts primarily by affecting signals in the brain that trigger cough, and also acts as an NMDA receptor antagonist, sigma-1 receptor agonist, and serotonin reuptake inhibitor[2][4][6][8]. - **Rosuvastatin** is an HMG-CoA reductase inhibitor (statin), used to lower cholesterol and prevent cardiovascular disease, acting by inhibiting the rate-limiting step in cholesterol biosynthesis. - **Digoxin** is a cardiac glycoside used in heart failure and atrial fibrillation, inhibiting Na+/K+-ATPase and increasing cardiac contractility. This specific combination does not correspond to a marketed drug product or branded combination; it is likely under investigation as a drug-drug interaction probe or in pharmacokinetic studies. Each agent has a distinct mechanism of action relevant to its approved indications; in a combination context, the study rationale may focus on the metabolism and interaction profiles of these agents, especially important for clinical pharmacology research.

Other names

JMKX001899JMKX-001899JMKX 001899dextromethorphanmidazolamrosuvastatindigoxin